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We studied the number and function of angiogenic progenitor cells and growth factors in children aged 5–18 years without acute
illness, 43 with Hemoglobin SS and 68 with normal hemoglobin. Hemoglobin SS subjects had at least twice as many mononuclear
cell colonies and more circulating progenitor cell than Control subjects. Plasma concentrations of erythropoietin, angiopoietin-
2, and stromal-derived growth factor (SDF)-1α were signiﬁcantly higher in children with Hemoglobin SS compared to Control
subjects.Inamultivariateanalysismodel,SDF-1αconcentrationwasfoundtobeassociatedwithbothCPCnumberandtotalwhite
blood cell count in the Hemoglobin SS group, suggesting that SDF-1α produced by ischemic tissues plays a role in mobilizing these
cells in children with Hemoglobin SS. Despite having a higher number of angiogenic progenitor cells, children with Hemoglobin
SS had slower migration of cultured mononuclear cells.
1.Introduction
Sickle cell anemia (Hemoglobin SS) is characterized by
hemoglobin polymerization and the formation of inﬂexible
sickled erythrocytes. Accumulation of sickled erythrocytes in
the microcirculation causes acute vaso-occlusive events that
lead to pain and acute organ injury. Chronic arterial vascu-
lopathy, with intimal proliferation and arterial stenosis, can
lead to complications such as stroke and pulmonary hyper-
tension. The etiology of arterial stenosis in sickle cell anemia
is poorly understood. We hypothesize that intimal prolife-
ration in sickle cell anemia is due to abnormal reparative
responses to ongoing vessel injury. Hemolytic anemia,
vaso-occlusion, and abnormal ﬂow dynamics in sickle cell
anemia may contribute to vessel injury. Chronic intravascu-
lar hemolysis releases free heme, which binds avidly to nitric
oxide (NO), causing NO depletion, and subsequent vaso-
constriction and inﬂammation [1]. Erythrocyte-derived
reactive iron and oxygen species are also directly injurious to
endothelium [2]. Repetitive episodes of acute vaso-occlusion
cause tissue ischemia and reperfusion, which also lead to
inﬂammation and increased oxidative stress [3]. Evidence
of ongoing inﬂammation and vascular injury is present in
peoplewithsicklecellanemiaevenwhenasymptomatic,with
elevated levels of high sensitivity C-reactive protein (hsCRP)
[4] and circulating endothelial cells [5].2 Anemia
Reendothelization after vascular injury is a critically
important process to restoring and maintaining vascular
homeostasis. Endothelial progenitor cells (EPCs) are recruit-
ed from the bone marrow and home to sites of vascular
injury.RecruitmentandhomingofEPCsareintimatelyregu-
lated by cytokines and growth factors released at the sites of
vascular insult. Reduced numbers of endothelial progenitor
colonies have been found in adults with cardiovascular risk
factors [6], diabetes [7], and those with established cerebrov-
ascular disease [8]. Cardiovascular disorders are also asso-
ciated with functional impairments in EPC migration or
angiogenesis [9]. Endothelial progenitor cells are elevated
during acute myocardial infarction [10], stimulated by
hematopoietic growth factors such as erythropoietin [11],
granulocyte colony-stimulating factor (G-CSF), or granu-
locyte-macrophage colony stimulating factor (GM-CSF),
and by treatment with HMG-CoA reductase inhibitors (sta-
tins) [12] or angiotensin-2 receptor antagonists [13].
To date, there is limited information about the number
and function of EPCs or the growth factors involved in
EPC recruitment and homing in people who have sickle cell
disease. Van Beem reported elevated numbers of circulating
EPCs (expressing CD34 and VEGFR2) in adults with Hemo-
globin SS or Sβ0-thalassemia during painful crisis, but there
was no diﬀerence between asymptomatic adults with sickle
cell disease and healthy controls [14]. The higher number
of circulating EPCs during painful crisis was associated with
increased serum levels of erythropoietin, soluble VCAM-1
(sVCAM-1), and vascular endothelial growth factor (VEGF).
Several angiogenic growth factors have been found to be
elevated in Hemoglobin SS. Angiopoietin (Ang)-2 and ery-
thropoietinwerehigherinadultswithHemgoglobinSScom-
pared to healthy controls and further elevated during acute
painful crisis [15]. Higher levels of vascular endothelial
g r o w t hf a c t o r( V E G F )w e r ef o u n di ns u b j e c t sw i t hH e m o -
globin SS compared to controls in some studies [16, 17], but
not in others [15]. When present, higher VEGF levels were
found to be associated with reduced odds of elevated tri-
cuspid valve regurgitant velocity by echocardiography in
children with sickle cell disease, a noninvasive measure sug-
gesting pulmonary artery hypertension [16]. Conversely,
children with sickle cell disease with elevated tricuspid
regurgitant velocity had higher concentrations of platelet-
derived growth factor (PDGF)-BB. Higher levels of SDF-1
havebeenfoundinadultswithHemoglobinSSthancontrols,
particularly in those who had pulmonary hypertension [18].
There is ongoing debate about the in vitro phenotype
of endothelial progenitor cells. Circulating cells expressing
hematopoietic stem cell marker CD34, vascular endothelial
growth factor receptor (VEGFR)-2, and early progenitor
marker CD133 have been considered to represent EPCs,
though recent studies show that these cells were immature
hematopoietic cells that did not diﬀerentiate into EPCs or
form vessels [19]. In a study of the eﬀects of granulocyte-
macrophage colony-stimulating factor (GM-CSF) on vascu-
lar function in adults with peripheral arterial disease, treat-
ment-induced increase in the number of circulating CD34-
expressing cells correlated with clinical improvements in
ﬂow-mediated dilation and pain-free walking time [20],
suggesting that undiﬀerentiated hematopoietic cells have
angiogenic potential or are a surrogate marker of vascular
repair cells. In this paper, we refer to the cultured cells as
mononuclear cells and the cells measured from the peri-
pheral blood as circulating progenitors cells (CPCs) with
angiogenic potential.
Taken together, there is evidence that people with sickle
cell disease have vessel injury and proangiogenic growth fac-
torresponses,butlimitedinformationaboutvascularrepara-
tive function in sickle cell disease. We hypothesize that vas-
cular complications in people with sickle cell disease arise
fromalteredrepairmechanisms,mostlikelyduetoabnormal
angiogenic cell functions. We expect CPC numbers to be
normal or elevated, stimulated by high levels of erythropoi-
etin that is seen with chronic anemia. We report here our
ﬁndings of cultured mononuclear colony and CPC number
in children with Hemoglobin SS versus healthy Controls,
their relationship to plasma levels of angiogenic growth fac-
tors, and the migration of cultured mononuclear cells.
2.MaterialsandMethods
2.1.BloodSampleCollection. Thestudyprotocolwasapprov-
ed by the Institutional Review Boards of Morehouse School
of Medicine and Children’s Healthcare of Atlanta, and the
Grady Hospital Research Oversight Committee. Written
informed consent was obtained from each participant’s
parent or guardian and verbal assent from the volunteer
before sample collection. Venous blood was collected from
African American children aged 5–18 years old without sym-
ptoms of acute illness. Controls had Hemoglobin AA or AC,
and sickle cell anemia subjects had Hemoglobin SS or Hb
S-β0 thalassemia. Children treated with hydroxyurea, recent
red blood cell transfusion within the previous 90 days, or
who had cardiovascular risk factors, such as overweight or
obesity, cigarette smoking, diabetes, or hypertension, were
excluded. Complete blood counts were performed by stand-
ard methods by the clinical laboratories used by the clinic
sites.
2.2. Circulating Progenitor Cell Quantitation. Whole blood
samples were labeled with monoclonal antibodies for FITC-
conjugated anti-human CD34 (clone 8G12, 0.6μg/mL ﬁnal
concentration, Becton Dickinson, Franklin Lakes, NJ), PE-
conjugated anti-human VEGFR2 (clone 89106, 1.2μg/mL,
R&D Systems, Minneapolis, MN), PERCP-conjugated anti-
human CD45 (clone 2D1, 0.6μg/mL, Becton Dickin-
son), APC-conjugated anti-human CD133/1 (clone AC133,
0.85μg/mL, Miltenyi Biotec Inc., Auburn, CA), and PE-
Cy7conjugatedanti-humanCXCR4(clone12G5, 0.5μg/mL,
eBioscience Inc., San Diego, CA), or their isotype controls
at the same concentrations, and analyzed by FACS. Thirty
microlitersofantibodycocktailwasaddedto300μLofwhole
blood, or 15μL of the isotype control cocktail was add-
ed to 150μL of blood. Samples were incubated in the
dark for 15 minutes. Red blood cells were lysed by adding
1.5mL of lysing solution (NH4Cl 0.15M, KHCO3 10mM,
EDTA 0.1mM) into each tube. Lysis was stopped by adding
1.5mL of staining media (phosphate-buﬀered saline [PBS]Anemia 3
without Mg++ or Ca++, heat-inactivated fetal calf serum 3%,
and NaN3 0.1%) and mixing gently. Immediately before
acquisition on a ﬂow cytometer, 100μL of Accucheck Count-
ing Beads (PCB100, Invitrogen) were added and mixed
gently. Cells were washed twice and resuspended in 500μL
of staining media. Samples were kept in the dark until run
on the ﬂow cytometer, within 4 hours of initial processing.
Data are reported for cells with low (dim) CD45 expression
(which excludes mature leukocytes).
2.3. Mononuclear Cell Colony Assay. Mononuclear cell cul-
ture was performed according to a modiﬁcation of the
protocolofHilletal.[6].Peripheralbloodmononuclearcells
(PBMCs) were isolated from whole blood by density frac-
tionation and cultured on ﬁbronectin-coated plates (Bec-
ton Dickinson) in M199 medium (Invitrogen, Carlsbad,
CA) with fetal calf serum 20% (Invitrogen) and penicillin
100U/mLandstreptomycin100μg/mL(Invitrogen),at37◦C
in 5% CO2. The same lot of fetal calf serum was used
throughout the study for all samples. After 48 hours, nonad-
herentcellswerereplatedataconcentrationof106 perwellin
ﬁbronectin-coated plates. Media were replenished every two
days. Colony-forming units (>200 micron diameter) in each
well were counted 7 days after replating. The reported num-
b e ro fc o l o n i e sp e rw e l li st h ea v e r a g eo f3w e l l sp e rs u b j e c t .
2.4. Immunoﬂuorescent Staining. Mononuclear cells were
seeded onto ﬁbronectin-coated four-chamber slides (Becton
Dickinson) at a concentration of 2 × 106 cells per chamber.
Cells were grown to conﬂuence over 14 days with media
replenishedeverytwodays.Conﬂuentmonolayerswereﬁxed
with 4% paraformaldehyde in PBS. Cells were permeabilized
with ice cold methanol for ﬁve minutes and blocked with
goat serum 10% (Dako, Carpinteria, CA) for one hour. Cells
were incubated overnight with murine primary antibodies
directed against human CD31 (clone JC70A, 10μg/mL ﬁnal
concentration, Dako), human endothelial nitric oxide syn-
thase (-eNOS, clone 3, 1.25μg/mL, Becton Dickinson),
human CD14 (clone TUK4, 0.5μg/mL, Dako) or isotype
controls at the same concentrations (mouse IgG1 or mouse
IgG2a, Dako), in PBS with goat serum 2%. Cells were
washedwithPBSandincubated foronehour withsecondary
antibodies (Alexaﬂuor (AF)-488 goat anti-mouse IgG1 or
AF-594 goat anti-mouse IgG2a, Invitrogen) at 1:500 dilution
in PBS with goat serum 2%. Slides were counterstained with
DAPI nuclear stain (Invitrogen).
2.5. Wound Migration Assay. Mononuclear cells were grown
until conﬂuent on ﬁbronectin-coated plates for 14 days, as
described above. An aseptic linear wound was made across
the mononuclear cell monolayer using sterile 20μL pipette
tip. Digital photographs were taken at 0 and 24 hours after
thewoundwasmade.Thewoundareawasmeasuredforeach
time point using image analysis software (Image-Pro Plus v.
6.2 for Windows, Bethesda, MD). The diﬀerence in wound
area between hours 0 and 24 was expressed as
%Area migrated =
AreaHr0 −AreaHr24
AreaHr0
× 100. (1)
The average wound area of 3 wells was reported for each
subject.
2.6. Angiogenic Growth Factor Assays. Quantitative enzyme-
linked immuno-sorbent assay (ELISA) for human erythro-
poietin, angiopoietin-2, and SDF-1α (R&D Systems, Min-
neapolis, MN), and a Human Angiogenesis Assay Panel
(BioRad, Hercules, CA) were used to measure plasma con-
centrationsofgrowthfactors.Resultsforerythropoietinwere
expressed as mIU/mL or pg/mL of plasma for the other
growth factors. Each ELISA sample was run in duplicate.
2.7. Oxidative Stress Markers. Plasma concentrations of the
redox pairs cysteine and cystine (Cys, CySS) and reduced
and oxidized glutathione (GSH, GSSG) were measured
by high pressure liquid chromatography (HPLC), and the
redox potentials for the Cys/CySS and GSH/GSSG couples
(EhCySS, EhGSSG, resp.) were calculated using the method
of Jones [21]. This method includes sample preparation and
storage procedures to reduce artifacts that can be caused
by hemolysis or GSH thiol-disulﬁde exchange. Urinary 8-
isoprostanes (8-iso-Prostaglandin-F2α)w e r em e a s u r e db y
ELISA (Enzo LifeLife Sciences, Plymouth Meeting, PA).
2.8. Classiﬁcation of Variables and Data
2.8.1. Outcome Variables. The main outcome variables were
blood-derived mononuclear cell colonies and CPC popula-
tions. Total white blood cell (WBC) count was analyzed as an
intermediate outcome variable.
2.8.2. Exposure Variables. The main exposure variable was
Hemoglobin Group, deﬁned as a categorical variable with
two levels, Hemoglobin SS and Control. The other exposure
variables were the clinical characteristics (age, weight, sex),
peripheral blood counts, angiogenic growth factors, and
oxidative stress markers.
2.9. Statistical Analysis. Data were summarized using fre-
quencies and percentages for categorical variables and means
(and standard deviation) for continuous variables. Data
that were not normally distributed were transformed using
natural logarithm transformation. The antilogarithms of the
means of the transformed data are reported as geometric
means.
2.9.1. Univariate Analyses. Simple linear regression models
were ﬁtted to determine the relationships between the num-
ber of each CPC type (outcome variables) and individual
clinical variables or biomarkers (exposure variables).
2.9.2.MultivariateAnalyses. Bivariatelinearregressionmod-
els were ﬁtted to examine the relationship between hemo-
globin group SS and number of CPCs, as well as the
confounding eﬀects of the other exposure variables. Con-
founders were deﬁned as those variables causing at least
25% reduction in the β-coeﬃcient compared to the main
exposure variable alone. Multiple linear regression analyses
were then performed to examine the relationship between4 Anemia
Table 1: Subject characteristics and hematologic parameters. There was no diﬀerence in age and sex of the participants in each group.
Hemoglobin SS subjects had signiﬁcantly lower hemoglobin concentration and higher WBC and platelet counts (indicated by asterisks (∗)).
Control Hemoglobin SS
P value
n Arithmetic mean
(95th% CI)
Geometric mean
(95th% CI) n Arithmetic mean
(95th% CI)
Geometric mean
(95th% CI)
Age (yrs) 68 12.8 (12–13.8) 12.3 (11.4–13.3) 43 12 (11–13) 11.5 (10.4–12.6) 0.26
Sex (males) 68 30 (44%) 43 20 (47%)
Hemoglobin (gm/dL) 39 13.6 (12.1–15.2) 13.2 (12.4–14.1) 19 8.4 (7.8–9) 8.3∗ (7.7–8.9) <0.001
WBC (×103/mL) 39 5.4 (4.9–6) 5.2 (4.7–5.7) 18 12.1 (9.6–14.4) 11.4∗ (9.7–13.4) <0.001
Platelets (×103/mL) 39 280 (261–298) 274 (257–293) 18 413 (373–454) 406∗ (368–448) <0.001
Table 2: Number of mononuclear cell colonies and CPCs for each Hemoglobin Group. Children with Hemoglobin SS had more
mononuclear cell colonies and circulating progenitor cells than Controls. Mononuclear cell colonies are reported per well, and CPCs in
cells/μL. Signiﬁcant diﬀerences in geometric means between Control and Hemoglobin SS groups are indicated by asterisks (∗).
Main exposure variables (Hemoglobin Group)
Outcome variables Control Hemoglobin SS Fold
diﬀerence P value
n Arithmetic mean
(95th% CI)
Geometric mean
(95th% CI) n Arithmetic mean
(95th% CI)
Geometric mean
(95th% CI)
Colonies 63 13.5 (8.5–18.5) 8.1 (5.8–11.5) 39 28.8 (16.1–41.6) 16.5∗ (11–24.6) 2 0.01
CD34 43 1.7 (1.3–2.1) 1.4 (1.2–1.7) 17 5.4 (2.3–8.5) 3.6∗ (2.3–5.6) 2.6 <0.001
CD34/CD133 43 1.0 (0.7–1.2) 0.8 (0.7–1.0) 17 2.0 (1.0–2.9) 1.3 (0.8–2.2) 0.1
CD34/CXCR4 43 0.6 (0.5–0.7) 0.48 (0.4–0.6) 17 3.2 (1.2–5.2) 1.66∗ (0.9–3.2) 3.5 <0.001
CD34/VEGFR2 43 0.12 (0.09–0.15) 0.08 (0.06–0.1) 17 0.68 (0.2–1.1) 0.36∗ (0.2–0.6) 2.6 <0.001
CD34/CXCR4/VEGFR2 43 0.2 (0.1–0.3) 0.1 (0.07–01) 17 0.6 (0.2–1) 0.29∗ (0.15–0.5) 2.9 0.002
hemoglobin group and number of CPCs, controlling for all
confounding variables.
Similar univariate and multivariate analyses were per-
formed using WBC as an intermediate outcome. All analyses
were performed using STATA Data Analysis and Statistical
software (College Station, TX), and level of statistical signiﬁ-
cance was set at 0.05.
3. Results
A total of 111 children were studied, 68 Controls and 43
with Hemoglobin SS. Clinical features are shown in Table 1.
As expected, children with Hemoglobin SS had signiﬁcantly
lowerhemoglobinconcentration,andhigherwhitebloodcell
and platelet counts than Controls. There were no signiﬁcant
diﬀerences in age or sex between the two groups.
3.1. Angiogenic Progenitor Cells. On average, twice as many
mononuclear cell colonies were grown from the blood of
children with Hemoglobin SS than healthy Control children
(geometric mean 16.5 versus 8.1 colonies/well, P<0.05)
(Table 2). A subset of the cultured cells expressed platelet
endothelial cell adhesion molecule (PECAM or CD31) and
endothelial nitric oxide synthase (eNOS), two markers of
mature endothelial cells (Figure 1). There was no signiﬁcant
diﬀerence in percentage of cultured cell expressing CD31 or
eNOS between Hemoglobin SS and Control groups, and the
cells did not express the monocytic marker, CD14 (data not
shown).
Similarly, there were at least twice as many CPCs express-
ing CD34,CD34/VEGFR2, CD34/CXCR4, orCD34/CXCR4/
VEGFR2 in the children with Hemoglobin SS compared
to Controls (Table 2), but no diﬀerence in the number of
cells expressing CD34/CD133. Circulating progenitor cells
expressing CD34/CD133/VEGFR2 are not reported due to
very low numbers. The diﬀerences between Hemoglobin SS
and Controls were highest in CPC expressing CXCR4 (SDF-
1α receptor). Thus, using two diﬀerent assay methods, we
found that asymptomatic children with Hemoglobin SS have
a higher number of circulating angiogenic progenitor cells.
3.2. Angiogenic Growth Factors. Plasma concentrations of
three angiogenic growth factors were signiﬁcantly higher in
children with Hemoglobin SS compared to Control sub-
jects: erythropoietin (13.5-fold), angiopoietin-2 (4-fold),
and stromal derived growth factor (1.7-fold) (Table 3). In
the angiogenesis multiplex assay, there were no signiﬁcant
diﬀerences between Hemoglobin SS and Control subjects
in plasma concentrations of vascular endothelial growth
factor (VEGF), hepatic growth factor (HGF), interleukin
(IL)-8, follistatin, platelet endothelial cell adhesion molecule
(PECAM)-1, or platelet-derived growth factor (PDGF-BB)
(20subjectstestedineachgroup)(datanotshown).Thecon-
centrations of the three elevated angiogenic growth factors
were found to be collinear, which is consistent with their
common regulation by hypoxia inducible factor (HIF) (data
not shown).Anemia 5
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Figure 1: Immunoﬂuorescent staining of cultured mononculear cells for endothelial antigens CD31 and endothelial nitric oxide synthase
(eNOS). CD31 and eNOS staining was observed in a subset of cells. A representative sample from a subject with Hemoglobin SS is shown.
(a) shows phase contrast image and (c) shows CD31 staining (green) with nuclei stained with DAPI (blue) in the same ﬁeld. (b) Shows phase
contrast and (d) shows eNOS staining (green) for the same sample.
3.3. Oxidative Markers. Both cysteine and cystine were sig-
niﬁcantly higher (1.5-fold) in the children with Hemoglobin
SS compared to Controls. There was no diﬀerence in levels
of reduced glutathione (GSH) between groups, whereas the
oxidized form of glutathione (GSSG) was 2-fold lower in
the children with Hemoglobin SS (Table 3). The calculated
redox potential for CyS/CySS (EhCySS) was signiﬁcantly
lower (more reduced) in the Hemoglobin SS group than
Controls, but there was no diﬀerence in EhGSSG between
groups. Urinary isoprostane levels were also not diﬀerent
between groups.
3.4. Wound Migration. Migration across a linear wound was
measured in a subset of mononuclear cell samples. Mono-
nuclear cells from Hemoglobin SS subjects (n = 5) migrat-
ed over a signiﬁcantly smaller percentage of the original
woundareain24hoursthancellsfromhealthyControls(n =
8) (28 versus 59%, respectively, P<0.01) (Figure 2). The
assay was not performed if samples had not grown to con-
ﬂuence within the 14–16-day culture period.
3.5. Multivariate Analyses. Supplementary Table 1 (available
online at doi:10.1155/2012/156598) shows the results of uni-
variate analyses. Circulating progenitor cell number was sig-
niﬁcantly associated with erythropoietin, angiopoietin, SDF-
1α, hemoglobin concentration, WBC and platelet counts,
and CySS and CySH levels. The strongest associations were
found with total WBC, SDF-1α, or erythropoietin.
A multivariate model was then used to test the role of
the exposure variables as possible determinants of the elevat-
ed number of CPCs in children with Hemoglobin SS. Total
white blood cell count was strongly associated with all
CPC types (Table 4). When CPC number was corrected
per 100 WBC, CD34/VEGFR2-expressing cells remained sig-
niﬁcantly higher in the Hemoglobin SS group than Controls
(mean 0.61 versus 0.25 per 100 WBC/μL, P = 0.04), but
there were no diﬀerences for the other CPC types. To test for
the eﬀects of the angiogenic growth factors alone, WBC was
excluded from the initial model.
Erythropoietin was associated with CD34 and CD34/
CXCR4 numbers, and angiopoietin-2 was associated with
CD34/CXCR4/VEGFR2 number. However, SDF-1α was con-
sistently associated with the number of all CPC types in
the Hemoglobin SS group (Table 5). SDF-1α in combination
with either erythropoietin or angiopoietin-2 had slightly
stronger associative eﬀects. None of the other exposure vari-
ables or biomarkers, including total hemoglobin, reticulo-
cytes, or platelet count were found to be associated with CPC
number in the Hemoglobin SS group.
White blood cells were then analyzed as a possible inter-
mediate outcome. In univariate analysis, total WBC was6 Anemia
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Figure 2: Mononuclear cell migration. Migration across a wound over 24 hours was signiﬁcantly less in children with Hemoglobin SS than
Controls.(a)showsarepresentativepairofControlandHemoglobinSSwoundmigrationassays.Thefreshlymadewoundwasphotographed
at 0 (zero) hours, and the area migrated is measured after 24 hours. (b) shows the cumulative data for 8 Control and 5 Hemoglobin SS
samples. The mean area migrated was less in children with Hemoglobin SS (28% versus 59% of the original wound area, P<0.01).
Table 3:Angiogenicgrowthfactorsandoxidant stressmarkersforeach Hemoglobin Group. Childrenwith Hemoglobin SS had higher levels
of three angiogenic growth factors, higher cysteine and cystine, and lower oxidized glutathione than Controls. Signiﬁcant diﬀerences in the
geometric means between Control and Hemoglobin SS groups are indicated by asterisks (∗).
Other exposure
variables
Main exposure variables (Hemoglobin Group)
Control Hemoglobin SS Fold
diﬀerence P value
n Arithmetic mean
(95th% CI)
Geometric mean
(95th% CI) n Arithmetic mean
(95th% CI)
Geometric mean
(95th% CI)
Erythropoietin
(IU/mL) 68 6.6 (4.8, 8.4) 4.2 (3.2, 5.5) 42 72.4 (55.6, 89) 56.6∗ (43.9, 73) 13.5 <0.001
Angiopoietin-2
(pg/mL) 45 1922 (1343, 2501) 1144 (809, 1616) 27 5946 (4661, 7231) 4968∗ (3820, 6461) 4.3 <0.001
SDF-1α (pg/mL) 64 2376 (2192, 2561) 2270 (2104, 2449) 38 4065 (3660, 4471) 3877∗ (3491, 4305) 1.7 <0.001
CyS (μM) 44 8.0 (7, 9) 7.4 (6.5, 8.4) 19 11.5 (9.5, 13.5) 10.8∗ (9, 13) 1.5 0.001
CySS (μM) 44 23.9 (22.3, 25.5) 23.4 (21.9, 24.9) 19 34.6 (30.4, 38.8) 33.7∗ (30, 37.8) 1.5 <0.001
EhCySS (mV) 44 −81.1 (−84,–78) 18
− 87.1∗ (−92,
−83) 0.026
GSH (μM) 44 1.1 (1, 1.2) 1.0 (0.9, 1.2) 19 1.1 (0.7, 1.5) 0.89 (0.7, 1.2) 0.38
GSSG (μM) 44 0.1 (0.08, 0.1) 0.08 (0.07, 0.1) 19 0.08 (0, 0.17) 0.04∗ (0.02, 0.07) 0.5 0.002
EhGSSG (mV) 44
−117.2
(−121, −113) 18 124.1
(−132, −117) 0.11
Urinary 8-isoprostanes
(ng/mL) 40 15 (9.7, 20.2) 8.88 (6.2, 12.7) 16 8.9 (7.2, 10.5) 8.4 (7, 10.1) 0.83
Table 4: Bivariate linear regression showing relationship between Hemoglobin SS group, WBC, and CPC types. WBC was found to be a
strongly associated with CPC number in the Hemoglobin SS group. Signiﬁcant reductions in the beta-coeﬃcient (>25%) compared to the
main exposure variable are marked with an asterisk (∗).
Outcome variables
Exposure variables CD34 CD34/CXCR4 CD34/VEGFR2 CD34/CXCR4/VEGFR2
β Adj r2 β Adj r2 β Adj r2 β Adj r2
Group = Hb SS 0.94 0.19 1.24 0.28 1.45 0.29 1.06 0.14
Hb SS + WBC −0.11∗ 0.36 0.22∗ 0.39 1.06∗ 0.29 0.32∗ 0.17Anemia 7
Table 5: Multivariate linear regression showing relationship between Hemoglobin SS group, angiogenic growth factors, and CPC
populations. SDF-1α was consistently associated with the relationship between Hemoglobin SS status and all CPC types (highlighted).
Signiﬁcant reductions in the beta-coeﬃcient (>25%) compared to the main exposure variable are marked with an asterisk (∗).
Outcome variables
Exposure variables CD34 CD34/CXCR4 CD34/VEGFR2 CD34/CXCR4/VEGFR2
β Adj r2 β Adj r2 β Adj r2 β Adj r2
Group = Hb SS 0.94 0.19 1.24 0.28 1.45 0.29 1.06 0.14
Hb SS + Erythropoietin 0.57∗ 0.16 0.51∗ 0.29 1.44 0.25 1.02 0.1
Hb SS + Angiopoietin-2 1.0 0.17 1.12 0.26 1.24 0.25 0.76∗ 0.11
Hb SS+SDF-1α 0.54∗ 0.18 0.68∗ 0.3 1.0∗ 0.27 0.37∗ 0.15
Hb SS+SDF-1α+Erythropoietin 0.42∗ 0.17 0.3∗ 0.31 1.24 0.26 0.54∗ 0.14
Hb SS+SDF-1α+Angiopoietin-2 0.71 0.19 0.73∗ 0.29 0.98∗ 0.26 0.3∗ 0.14
Table 6: Multivariate linear regression showing relationship
between Hemoglobin SS group, angiogenic growth factors, and
WBC. Each angiogenic growth factor was strongly associated with
the relationship between Hemoglobin SS and WBC. Signiﬁcant
reductions in the beta-coeﬃcient (>25%) compared to the main
exposure are marked with an asterisk (∗).
Intermediate outcome variable
Exposure variables WBC
β Adj r2
Group = Hb SS 0.79 0.73
Hb SS + Erythropoietin 0.007 0.26
Hb SS + Angiopoietin-2 <0.001 0.17
Hb SS + SDF-1α 0.004 0.32
found to have a similar pattern of relationships to the expo-
sure variables as the CPCs (Supplementary Table2). Multi-
variate analysis showed that each of the hypoxia-inducible
angiogenic growth factors was strongly associated with the
relationship between Hemoglobin SS group and elevated
WBC (Table 6).
4. Discussion
Vascular complications of sickle cell anemia, such as stroke
and pulmonary hypertension, begin in childhood and are
characterized by early development of intimal proliferation
in cerebral and pulmonary arteries in the absence of cardio-
vascularriskfactors,suchashypertensionorhyperlipidemia.
The mechanisms linking the primary genetic mutation in β-
globin structure to the development of intimal proliferation
andarterialstenosisareunknown.Wehypothesizethatsickle
cell anemia is associated with abnormal vascular repair.
We have found that children with sickle cell anemia have
a pro-angiogenic phenotype, with a higher numbers of cul-
tured mononuclear cells that express mature endothelial
markers, and CPCs with angiogenic potential, and higher
angiogenic growth factor levels. The higher number of
CPCsinHemoglobinSSwasassociatedwithhypoxia-induci-
ble angiogenic growth factors, either individually or in
combination. Stromal derived factor-1α was found to be
associated with the number of all CPC types in children
with Hemoglobin SS. In contrast, the severity of anemia
(hemoglobin level) was not associated with CPC number.
White blood cell count was found to be an intermediate out-
come, responding in a similar way to the hypoxia-inducible
angiogenic growth factors. When corrected for WBC, the
number of CD34/VEGFR2 cells was higher in the Hemoglo-
bin SS group, while there were no diﬀerences in the other
CPC populations. This implies that the elevation in most
of the CPC populations in Hemoglobin SS was a secondary
eﬀect of WBC mobilization, but that the number of circulat-
ing CD34/VEGFR2 cells was independent of elevated WBC.
Despite a higher number of CPCs in children with
Hemoglobin SS, cultured mononuclear cells in this group
migrated over a smaller area in a 24-hour period, suggesting
abnormal reparative function. The wound migration assay is
a well-established functional assay for endothelial progenitor
cells.Alimitationofourstudyisthesmallnumberofsubjects
whose cells were tested in the wound migration assay. The
wound assay was not performed when the cells did not form
a conﬂuent monolayer within the two-week culture period.
If the cells were tested after becoming conﬂuent over a longer
cultureperiod,wewereconcernedthatcellsenescencewould
contribute to variability in the results. Therefore, our results
represent only those samples with better in vitro cell growth.
Our ﬁndings suggest that bone marrow-derived CD34/
VEGFR2 cells in asymptomatic children with Hemoglobin
SS are mobilized by hypoxia-inducible angiogenic growth
factors from ongoing tissue ischemia, probably due to sub-
clinical sickle cell vaso-occlusion. We predict that numbers
will be elevated during acute sickle cell complications, that
there will be progressive decline in both CPC number and
function with increasing age, and that those individuals with
the most severe vascular complications may have impaired
function.Ifvalidatedasaconsistentﬁnding,impairedmono-
nuclear cell migration may be due to alterations in SDF-
1α-mediated CXCR4 signaling. Endothelial progenitor cells
from people with coronary artery disease were found to
have slower migration, reduced vascular tube formation,
and less eﬀect in restoring circulation in a rodent ischemic
limbmodel,inassociationwithlowerSDF-1α-inducedphos-
phorylation of JAK-2, a downstream target of CXCR4 [22].8 Anemia
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Figure 3: Diagram of CPC and WBC mobilization by vaso-
occlusion induced tissue ischemia. Vaso-occlusion by sickled red
blood cells (RBCs, red) results in tissue ischemia and reperfusion
(navy blue). Repeated episodes of vascular ischemia are likely
to promote vessel injury (black). Green arrows depict balanced
physiologic processes that aim to restore equilibrium. Hypoxia-
induciblefactor(HIF,gray) producedbyischemictissuesstimulates
angiogenic growth factors and bone marrow mobilization of angio-
genic progenitor cells (CPCs, brown) that participate in vascular
repair, white blood cells (light blue) that promote inﬂammation,
and more sickle red blood cells.
If functional abnormalities in EPCs can be identiﬁed and
corrected, EPCs in people with sickle cell disease can pos-
sibly be harnessed as cellular therapy to prevent or treat vas-
culopathy.
In addition, our data suggest that elevated WBC count
in children with Hemoglobin SS is also due to mobilization
by hypoxia-inducible angiogenic growth factors produced
by tissue ischemia. This ﬁnding provides a mechanistic link
between vaso-occlusion and the well-described elevations
of white blood cells and inﬂammatory mediators in sickle
cell disease (Figure 3). This relationship is consistent with
ﬁndings from the Cooperative Study of Sickle Cell Disease
(CSSCD) and a more recent cohort study, which describe
elevated baseline leukocytosis as a risk factor for adverse
sickle cell disease complications [23, 24]. Total WBC in the
asymptomatic state, when not modiﬁed by transfusion or
hydroxyurea therapy, may be a biomarker for tissue ischemia
in sickle cell disease.
5. Conclusions
We found angiogenic CPC number to be elevated in this
group of asymptomatic children with Hemoglobin SS, while
mononuclear cell migration was slower than in healthy Con-
trolchildren.Stromal-derivedfactor-1α,ahypoxia-inducible
angiogenic growth factor, is strongly associated with the
elevated numbers of CPCs and total WBC in children with
Hemoglobin SS. Tissue ischemia resulting from vaso-occlu-
sion may promote both proangiogenic and proinﬂammatory
states in sickle cell disease.
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